The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, and Rigshospitalet Gentofte, Hellerup, Denmark.
The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark.
Arthritis Care Res (Hoboken). 2019 Jun;71(6):798-810. doi: 10.1002/acr.23693. Epub 2019 May 2.
To study the prognostic value of widespread pain and of musculoskeletal ultrasound (US) examination for subsequent treatment outcomes in patients with psoriatic arthritis (PsA).
An exploratory prospective cohort study enrolled patients with PsA initiating biologic or conventional synthetic disease-modifying antirheumatic drugs in routine care. Clinical, US, and patient-reported measures were collected at baseline and after 4 months. Widespread nonarthritic pain (WP) was defined as a Widespread Pain Index score of ≥4 with pain in ≥4 of 5 regions. PsA activity by US was defined as color Doppler (yes/no) in selected entheses, joints, or tendons. The main response criteria included the American College of Rheumatology 20% improvement, the Disease Activity in Psoriatic Arthritis 50% improvement, and minimal disease activity. The primary analyses were age- and sex-adjusted logistic regression.
WP was present in 24 of 69 included patients (35%) and was associated with worse patient-reported and composite baseline measures, while US and other objective findings were similar to those in patients without WP. The odds of reaching minimal disease activity after 4 months were significantly greater for patients enrolled without WP (odds ratio 18.43 [95% confidence interval 1.51, 224.41]; P = 0.022), while WP did not impair other response measures. Patients with baseline color Doppler activity (n = 42 [61%]) had a worse objective PsA burden, but their chance of treatment response was comparable to those without color Doppler.
More than one-third of patients with PsA presented with WP, which was associated with worse patient-reported scores and failure to achieve minimal disease activity following conventional synthetic or biologic disease-modifying antirheumatic drug therapy. PsA activity by color Doppler US had no influence on subsequent treatment response in this PsA cohort.
研究广泛疼痛和肌肉骨骼超声(US)检查对银屑病关节炎(PsA)患者后续治疗结局的预后价值。
一项探索性前瞻性队列研究纳入了在常规护理中开始使用生物制剂或传统合成疾病修饰抗风湿药物治疗的 PsA 患者。在基线和 4 个月后收集临床、US 和患者报告的测量值。广泛性非关节炎疼痛(WP)定义为广泛性疼痛指数评分≥4,5 个区域中疼痛≥4 个。US 定义的 PsA 活动为选定的附着点、关节或肌腱的彩色多普勒(是/否)。主要反应标准包括美国风湿病学会 20%改善、银屑病关节炎 50%改善和最小疾病活动度。主要分析为年龄和性别调整的逻辑回归。
69 例纳入患者中有 24 例(35%)存在 WP,与患者报告和基线综合测量较差相关,而 US 和其他客观发现与无 WP 的患者相似。4 个月后达到最小疾病活动度的患者,无 WP 组的可能性显著增加(优势比 18.43[95%置信区间 1.51,224.41];P=0.022),而 WP 并未损害其他反应措施。基线有彩色多普勒活动(n=42[61%])的患者有更严重的客观 PsA 负担,但他们的治疗反应机会与无彩色多普勒的患者相当。
超过三分之一的 PsA 患者存在 WP,这与患者报告的评分较差以及在接受传统合成或生物疾病修饰抗风湿药物治疗后无法达到最小疾病活动度有关。在该 PsA 队列中,US 检测的彩色多普勒活动对后续治疗反应没有影响。